Literature DB >> 24187454

Gut-lung crosstalk in pulmonary involvement with inflammatory bowel diseases.

Hui Wang1, Jing-Shi Liu, Shao-Hua Peng, Xi-Yun Deng, De-Mao Zhu, Sara Javidiparsijani, Gui-Rong Wang, Dai-Qiang Li, Long-Xuan Li, Yi-Chun Wang, Jun-Ming Luo.   

Abstract

Pulmonary abnormalities, dysfunction or hyper-reactivity occurs in association with inflammatory bowel disease (IBD) more frequently than previously recognized. Emerging evidence suggests that subtle inflammation exists in the airways among IBD patients even in the absence of any bronchopulmonary symptoms, and with normal pulmonary functions. The pulmonary impairment is more pronounced in IBD patients with active disease than in those in remission. A growing number of case reports show that the IBD patients develop rapidly progressive respiratory symptoms after colectomy, with failure to isolate bacterial pathogens on repeated sputum culture, and often request oral corticosteroid therapy. All the above evidence indicates that the inflammatory changes in both the intestine and lung during IBD. Clinical or subclinical pulmonary inflammation accompanies the main inflammation of the bowel. Although there are clinical and epidemiological reports of chronic inflammation of the pulmonary and intestinal mucosa in IBD, the detailed mechanisms of pulmonary-intestinal crosstalk remain unknown. The lung has no anatomical connection with the main inflammatory site of the bowel. Why does the inflammatory process shift from the gastrointestinal tract to the airways? The clinical and subclinical pulmonary abnormalities, dysfunction, or hyper-reactivity among IBD patients need further evaluation. Here, we give an overview of the concordance between chronic inflammatory reactions in the airways and the gastrointestinal tract. A better understanding of the possible mechanism of the crosstalk among the distant organs will be beneficial in identifying therapeutic strategies for mucosal inflammatory diseases such as IBD and allergy.

Entities:  

Keywords:  Biao-Li relationship; Gut-lung crosstalk; Inflammatory bowel disease; Pulmonary symptoms; Social manner

Mesh:

Substances:

Year:  2013        PMID: 24187454      PMCID: PMC3812478          DOI: 10.3748/wjg.v19.i40.6794

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  116 in total

1.  THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS. III. COMPLICATIONS.

Authors:  F C EDWARDS; S C TRUELOVE
Journal:  Gut       Date:  1964-02       Impact factor: 23.059

2.  Changes in pulmonary function in patients with ulcerative colitis.

Authors:  Aliaë A R Mohamed-Hussein; Nadia A S Mohamed; Mohamed-Eltaher A R Ibrahim
Journal:  Respir Med       Date:  2006-10-17       Impact factor: 3.415

Review 3.  The epithelial gatekeeper against food allergy.

Authors:  Linda Chia-Hui Yu
Journal:  Pediatr Neonatol       Date:  2009-12       Impact factor: 2.083

4.  Experimental study on the mechanism of protective effect of free Fu on gut-derived endotoxin-mediated lung damage.

Authors:  Daoben Li; Shenglan Yang; Rui Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

5.  Venous thromboembolism in inflammatory bowel disease.

Authors:  Craig A Solem; Edward V Loftus; William J Tremaine; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2004-01       Impact factor: 10.864

6.  Acute pancreatitis in Crohn's disease.

Authors:  P Weber; F Seibold; H Jenss
Journal:  J Clin Gastroenterol       Date:  1993-12       Impact factor: 3.062

Review 7.  Musculoskeletal manifestations of inflammatory bowel disease.

Authors:  Leonidas A Bourikas; Konstantinos A Papadakis
Journal:  Inflamm Bowel Dis       Date:  2009-04-30       Impact factor: 5.325

8.  Increased frequency of bronchial hyperresponsiveness in patients with inflammatory bowel disease.

Authors:  E Louis; R Louis; V Drion; V Bonnet; A Lamproye; M Radermecker; J Belaiche
Journal:  Allergy       Date:  1995-09       Impact factor: 13.146

9.  Large airway disease associated with inflammatory bowel disease.

Authors:  A Spira; R Grossman; M Balter
Journal:  Chest       Date:  1998-06       Impact factor: 9.410

10.  Skin manifestations of inflammatory bowel disease.

Authors:  Brian L Huang; Stephanie Chandra; David Quan Shih
Journal:  Front Physiol       Date:  2012-02-06       Impact factor: 4.566

View more
  36 in total

Review 1.  Lung inflammation and disease: A perspective on microbial homeostasis and metabolism.

Authors:  Roberto Mendez; Sulagna Banerjee; Sanjoy K Bhattacharya; Santanu Banerjee
Journal:  IUBMB Life       Date:  2018-11-22       Impact factor: 3.885

Review 2.  [Aspects of pulmonary involvement in inflammatory bowel disease].

Authors:  A Moeser; M Lerche; H Wirtz; A Stallmach
Journal:  Internist (Berl)       Date:  2018-09       Impact factor: 0.743

Review 3.  Microbes, metabolites, and the gut-lung axis.

Authors:  Anh Thu Dang; Benjamin J Marsland
Journal:  Mucosal Immunol       Date:  2019-04-11       Impact factor: 7.313

Review 4.  The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development.

Authors:  David Briskey; Patrick Tucker; David W Johnson; Jeff S Coombes
Journal:  Clin Exp Nephrol       Date:  2016-03-10       Impact factor: 2.801

Review 5.  Gut Microbiota: the Emerging Link to Lung Homeostasis and Disease.

Authors:  An Zhou; Yuanyuan Lei; Li Tang; Shiping Hu; Min Yang; Lingyi Wu; Shiming Yang; Bo Tang
Journal:  J Bacteriol       Date:  2021-01-25       Impact factor: 3.490

6.  Original Research: Extract of Bambusae Caulis in Taeniam inhibits cigarette smoke-induced pulmonary and intestinal inflammation.

Authors:  Dahae Lim; Youngwoo Cho; Woogyeong Kim; Sehee Jeong; Young Pyo Jang; Jinju Kim
Journal:  Exp Biol Med (Maywood)       Date:  2016-09-02

7.  Melatonin reduces inflammation in intestinal cells, organoids and intestinal explants.

Authors:  Xiao-Qiang Yuan; Xu-Ming Zhang
Journal:  Inflammopharmacology       Date:  2021-08-24       Impact factor: 4.473

Review 8.  ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy.

Authors:  Colleen T Cole-Jeffrey; Meng Liu; Michael J Katovich; Mohan K Raizada; Vinayak Shenoy
Journal:  J Cardiovasc Pharmacol       Date:  2015-12       Impact factor: 3.105

Review 9.  Host responses to mucosal biofilms in the lung and gut.

Authors:  Jada C Domingue; Julia L Drewes; Christian A Merlo; Franck Housseau; Cynthia L Sears
Journal:  Mucosal Immunol       Date:  2020-02-28       Impact factor: 7.313

Review 10.  Cell-Cell Interaction Mechanisms in Acute Lung Injury.

Authors:  Huiting Zhou; Erica K Fan; Jie Fan
Journal:  Shock       Date:  2021-02-01       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.